文献速递乳腺癌

卢卡帕尼用于无胚系BRCA1/2突变的同源重组缺陷转移性乳腺癌患者

Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation.
PubMed 文献 · Eur J Cancer · 2021-11-25

RUBY单臂II期试验纳入42例无胚系BRCA1/2突变的HER2阴性转移性乳腺癌患者,40例接受至少一剂卢卡帕尼,主要终点临床获益率未达到,为13.5%。两例LOH高分且无体细胞BRCA1/2突变的患者获得完全且持久缓解,HRDetect与缓解的关联未达统计学显著。

要点

  • 卢卡帕尼在无胚系BRCA1/2突变的HER2阴性转移性乳腺癌中临床获益率为13.5%,未达到预设的20%主要终点。
  • 两例LOH高分且无体细胞BRCA1/2突变的患者获得完全且持久缓解,持续时间分别为12个月和28.5个月。
  • HRDetect与卢卡帕尼缓解的关联未达统计学显著(缓解者中位0.465 vs 非缓解者0.040,p=0.2135)。

核心结论

  • 数据提示一小部分LOH高分且无胚系BRCA1/2突变的患者可能从PARP抑制剂中获益。
  • RUBY研究强调需要开发更多生物标志物以选择性识别潜在缓解者。

研究设计与样本

  • 单臂II期RUBY试验纳入42例患者,其中40例接受至少一剂卢卡帕尼。
  • 研究采用两阶段Simon设计,把握度基于20%的临床获益率。
  • 主要终点为临床获益率,评估卢卡帕尼在HER2阴性转移性乳腺癌伴高基因组杂合性缺失评分或无胚系BRCA1/2突变患者中的疗效。

主要发现

  • 主要终点未达到,临床获益率为13.5%。
  • 两例LOH高分且无体细胞BRCA1/2突变的患者获得完全且持久缓解,持续时间分别为12个月和28.5个月。
  • 对24份样本进行全基因组分析,包括5例从卢卡帕尼获得临床获益的患者。
  • HRDetect与卢卡帕尼缓解的关联未达统计学显著(缓解者中位0.465 vs 非缓解者0.040,p=0.2135)。
  • 在RUBY上游筛查LOH的711例转移性乳腺癌患者中,220例呈现高LOH评分,与更高的死亡可能性相关(风险比=1.39;95%CI:1.11-1.75;p=0.005)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Breast cancer may present genomic alterations leading to homologous recombination deficiency (HRD). PARP inhibitors have proven their efficacy in patients with HER2-negative (HER2-) metastatic breast cancer (mBC) harbouring germline (g) BRCA1/2 mutations in 3 phases III trials. The single-arm phase II RUBY trial included 42 patients, 40 of whom received at least one dose of rucaparib. RUBY study assessed the efficacy of rucaparib in HER2-mBC with either high genomic loss of heterozygosity (LOH) score or non-germline BRCA1/2 mutation. PATIENTS AND METHODS: The primary objective was the clinical benefit rate (CBR), and the study was powered to see 20% CBR using a 2-stage Simon design. RESULTS: The primary-end point was not reached with a CBR of 13.5%. Two LOH-high patients, without somatic BRCA1/2 mutation, presented a complete and durable response (12 and 28.5 months). Whole-genome analysis was performed on 24 samples, including 5 patients who presented a clinical benefit from rucaparib. HRDetect tended to be associated with response to rucaparib, without reaching statistical significance (median HRDetect responders versus non-responders: 0.465 versus 0.040; p = 0.2135). Finally, 220 of 711 patients with mBC screened for LOH upstream from RUBY presented a high LOH score associated with a higher likelihood of death (hazard ratio = 1.39; 95% CI: 1.11-1.75; p = 0.005). CONCLUSION: Our data suggest that a small subset of patients with high LOH scores without germline BRCA1/2 mutation could derive benefit from PARP inhibitors. However, the RUBY study underlines the need to develop additional biomarkers to identify selectively potential responders.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Patsouris A, Diop K, Tredan O, et al. Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation. Eur J Cancer. 2021. PMID: 34837859. doi:10.1016/j.ejca.2021.09.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。